Innovation Pharmaceuticals and George Mason University&rsquo;s National Center for Biodefense and Infectious Diseases (NCBID) have completed extensive pre-clinical laboratory testing demonstrating the potent anti-SARS-CoV-2 activity of Brilacidin, a defensin-mimetic drug candidate, which is being developed as a potential COVID-19 treatment. 

Innovation Pharmaceuticals

Wakefield

Innovation Pharmaceuticals startup from Wakefield, United States is ranked 957 out of 2449 worldwide and 352 from the 748 startups in United States. See more information and additional rankings on the StartupBlink Global Ecosystem Map